1. Please check and comment entries here.
Table of Contents

    Topic review

    Inhibitors for Novel Coronavirus Protease

    View times: 130
    Submitted by: Markus Lill


    The rapid outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China followed by its spread around the world poses a serious global concern for public health. To this date, no specific drugs or vaccines are available to treat SARS-CoV-2. Thus, there remains an urgent need for the development of specific antiviral therapeutics against SARS-CoV-2. To conquer viral infections, the inhibition of proteases essential for proteolytic processing of viral polyproteins is a conventional therapeutic strategy. In order to find novel inhibitors, we computationally screened a compound library of over 606 million compounds for binding at the recently solved crystal structure of the main protease (Mpro) of SARS-CoV-2. A screening of such a vast chemical space for SARS-CoV-2 Mpro inhibitors has not been reported before. After shape screening, two docking protocols were applied followed by the determination of molecular descriptors relevant for pharmacokinetics to narrow down the number of initial hits. Next, molecular dynamics simulations were conducted to validate the stability of docked binding modes and comprehensively quantify ligand binding energies. After evaluation of potential off-target binding, we report a list of 12 purchasable compounds, with binding affinity to the target protease that is predicted to be more favorable than that of the cocrystallized peptidomimetic compound. In order to quickly advise ongoing therapeutic intervention for patients, we evaluated approved antiviral drugs and other protease inhibitors to provide a list of nine compounds for drug repurposing. Furthermore, we identified the natural compounds (−)-taxifolin and rhamnetin as potential inhibitors of Mpro.

    1. Introduction

    In late 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was determined as a cause for several cases of respiratory disease in China. Even though most infected patients only suffer from mild symptoms such as fever and cough associated with a good prognosis, the disease can progress into fatal cases of pneumonia and acute respiratory failure, especially in older people with comorbidities [1][2]. The virus rapidly spread from China to over 141 countries worldwide and, up to this date, infected almost two million people claiming more than 100,000 fatalities [3] (as of 14 April 2020), already exceeding the 2003 SARS-CoV epidemic [4]. Most probably, the virus originated from a zoonotic transmission between animals such as bats and humans but progressed to transmit from human to human through common droplet infection [2][5][6]. The World Health Organisation declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern [7][8] and, based on the 2003 epidemic of SARS-CoV, it will lead to the loss of many lives exerting enormous social impact and economic loss [9]. Clinical treatment of the disease is mainly symptomatic and based on repurposing of already marketed antiviral drugs such as ritonavir and antibiotics to treat secondary infections [1]. Thus, there remains an urgent need for the development of specific antiviral therapeutics and vaccines against SARS-CoV-2 [4][10][11][12].

    The inhibition of viral proteases necessary for proteolytic processing of polyproteins has been a successful strategy in the pharmacological treatment of human immunodeficiency virus (HIV) and hepatitis C virus, respectively [13][14], proving the potential of protease inhibitors for the treatment of viral infections. Similarly, the main protease (Mpro) of SARS-CoV-2 is thought to be essential for viral replication and, therefore, is regarded as promising target for antiviral pharmacotherapy [10][15]. The crystal structure of the SARS-CoV-2 main protease was recently solved [16] which enables the rational design of specific inhibitory compounds. The close relationship of SARS-CoV-2 to SARS-CoV is reflected by the high sequence identity of 96.1% among their Mpro [17][10]. In this regard, it was suggested that compounds developed against SARS-CoV might be effective to treat SARS-CoV-2 [12] and can therefore be considered as template structures for Mpro inhibitors. However, these compounds remained in the preclinical or early clinical stage and did not lead to approved therapeutics [18]. Furthermore, their effectiveness for the novel virus might suffer due to differences in individual amino acids [19] as we discuss in the beginning of the next section. Accordingly, the development of specific inhibitors for SARS-CoV-2 main protease remains an urgent necessity in the scientific community [10][11][12] which is reflected by the multiple projects focusing on this protein. For example, three studies investigating the repurposing of marketed drugs proposed several candidates for SARS-CoV-2 treatment [10][15][20][21]. In another recent study, a deep learning approach based on a fully connected neural network trained on the PDBBind database [22] combined with a homology model of the protease was applied to screen a library of approximately one million compounds including already approved drugs, tripeptides, and natural products [12]. However, the disadvantage of applying therapeutics originally designed for a different target is the risk of undesired pharmacological effects and adverse reactions [23]. Even though vaccine development can be assisted by computational methods [24], this study is focused on the design of a small-molecule enzyme inhibitor.

    2. Development

    In this study, we screened a large library of over 606 million compounds with the aim to discover novel inhibitors for the SARS-CoV-2 main protease. We designed a protocol consisting of a combination of intensively validated methods that were successfully applied in drug discovery programs either as standalone tools or in combination [25][26][27][28]. In a first step, we performed a shape-based screening with known binders for the SARS-CoV main protease and relevant substructures as template molecules. After the initial shape screening, two different docking protocols were applied followed by the assessment with pharmacokinetic filters to narrow down the number of potential binders. Clustering based on molecular fingerprints was applied to ensure structural diversity of the compounds that were, in the next step, subjected to molecular dynamics (MD) simulations. Based on the obtained trajectories, the binding free energy of the ligands was quantified using Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) post-processing. In the last step, we assessed potential toxic effects of the compounds due to the interaction with 16 known off-targets to make a final selection of 12 compounds. In addition, we report the highest scored natural compounds and a list of marketed drugs that could be repurposed for SARS-CoV-2 treatment. Such a comprehensive exploration of chemical space intending to discover SARS-CoV-2 Mpro inhibitors was, to the best of our knowledge, not previously reported.

    This entry is adapted from 10.3390/ijms21103626


    1. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020, 395, 507–513.
    2. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273.
    3. World Health Organisation. Novel Coronavirus (2019-nCoV) Situation Reports; World Health Organisation: Geneva, Switzerland, 2020.
    4. Wang, F.; Chen, C.; Tan, W.; Yang, K.; Yang, H. Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design. Sci. Rep. 2016, 6, 22677.
    5. Chen, Z.M.; Fu, J.F.; Shu, Q.; Chen, Y.H.; Hua, C.Z.; Li, F.B.; Lin, R.; Tang, L.F.; Wang, T.L.; Wang, W.; et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J. Pediatr. WJP 2020.
    6. Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579, 265–269.
    7. World Health Organisation. International Health Regulations Emergency Committee on Novel Coronavirus in China; World Health Organisation: Geneva, Switzerland, 2020.
    8. Stoermer, M.J. Homology Models of the Papain-Like Protease PLpro from Coronavirus 2019-nCoV. ChemRxiv 2020.
    9. Keogh-Brown, M.R.; Smith, R.D. The economic impact of SARS: How does the reality match the predictions? Health Policy 2008, 88, 110–120.
    10. Xu, Z.; Peng, C.; Shi, Y.; Zhu, Z.; Mu, K.; Wang, X.; Zhu, W. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. BioRxiv 2020, 1201, 1–20.
    11. Zumla, A.; Hui, D.S.; Azhar, E.I.; Memish, Z.A.; Maeurer, M. Reducing mortality from 2019-nCoV: Host-directed therapies should be an option. Lancet 2020, 395, e35–e36.
    12. Zhang, H.; Saravanan, K.M.; Yang, Y.; Hossain, T. Deep learning based drug screening for novel coronavirus 2019-nCov. Preprints 2020, 19, 1–17.
    13. Yang, S.; Chen, S.J.; Hsu, M.F.; Wu, J.D.; Tseng, C.T.K.; Liu, Y.F.; Chen, H.C.; Kuo, C.W.; Wu, C.S.; Chang, L.W.; et al. Synthesis, Crystal Structure, Structure-Activity Relationships, and Antiviral Activity of a Potent SARS Coronavirus 3CL Protease Inhibitor. J. Med. Chem. 2006, 49, 4971–4980.
    14. Ghosh, A.K.; Osswald, H.L.; Prato, G. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. J. Med. Chem. 2016, 59, 5172–5208.
    15. Liu, X.; Wang, X.J. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J. Genet. Genom. 2020.
    16. Liu, X.; Zhang, B.; Jin, Z.; Yang, H.; Rao, Z. The Crystal Structure of COVID-19 Main Protease in Complex with an Inhibitor N3; Protein DataBank: New York, NY, USA, 2020.
    17. Li, Y.; Zhang, J.; Wang, N.; Li, H.; Shi, Y.; Guo, G.; Liu, K.; Zeng, H.; Zou, Q. Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening. bioRxiv 2020, 922922.
    18. Pillaiyar, T.; Manickam, M.; Namasivayam, V.; Hayashi, Y.; Jung, S.H. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy. J. Med. Chem. 2016, 59, 6595–6628.
    19. Raugi, D.N.; Smith, R.A.; Gottlieb, G.S. Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J. Virol. 2016, 90, 1062–1069.
    20. Chen, Y.W.; Yiu, C.P.; Wong, K.Y. Prediction of the 2019-nCoV 3C-like protease (3CLpro) structure_ virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.pdf.crdownload. ChemRxiv 2020.
    21. Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.; et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B 2020.
    22. Liu, Z.; Li, Y.; Han, L.; Li, J.; Liu, J.; Zhao, Z.; Nie, W.; Liu, Y.; Wang, R. PDB-wide collection of binding data: Current status of the PDBbind database. Bioinformatics 2014, 31, 405–412.
    23. Vedani, A.; Dobler, M.; Hu, Z.; Smieško, M. OpenVirtualToxLab-A platform for generating and exchanging in silico toxicity data. Toxicol. Lett. 2015, 232, 519–532.
    24. He, L.; Zhu, J. Computational tools for epitope vaccine design and evaluation. Curr. Opin. Virol. 2015, 11, 103–112.
    25. Corso, G.; Alisi, M.A.; Cazzolla, N.; Coletta, I.; Furlotti, G.; Garofalo, B.; Mangano, G.; Mancini, F.; Vitiello, M.; Ombrato, R. A Novel Multi-step Virtual Screening for the Identification of Human and Mouse mPGES-1 Inhibitors. Mol. Inform. 2016, 91045543, 358–368.
    26. Du, J.; Sun, H.; Xi, L.; Li, J.; Yang, Y.; Liu, H.; Yao, X. Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM-GBSA calculation. J. Comput. Chem. 2011, 32, 2800–2809.
    27. Ye, W.L.; Yang, S.Q.; Zhang, L.X.; Deng, Z.K.; Li, W.Q.; Zhang, J.W.; Zhang, L.; Yun, Y.H.; Chen, A.F.; Cao, D.S. Multistep virtual screening for rapid identification of G Protein-Coupled Receptors Kinase 2 inhibitors for heart failure treatment. Chemom. Intell. Lab. Syst. 2019, 185, 32–40.
    28. Kotowski, K.; Supplitt, S.; Wiczew, D.; Przystupski, D.; Bartosik, W.; Saczko, J.; Rossowska, J.; Dra̧g-Zalesińska, M.; Michel, O.; Kulbacka, J. 3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/ Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells. Anticancer Res. 2020, 40, 2613–2625.